—
The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Anemia and features dormant and discontinued projects.Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Complete Report @ https://www.wiseguyreports.com/reports/643479-chemotherapy-induced-anemia-pipeline-review-h2-2016
Scope
- The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Anemia
- The report reviews pipeline therapeutics for Chemotherapy Induced Anemia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Chemotherapy Induced Anemia therapeutics and enlists all their major and minor projects
- The report assesses Chemotherapy Induced Anemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Chemotherapy Induced Anemia
Get Sample Report @ https://www.wiseguyreports.com/sample-request/643479-chemotherapy-induced-anemia-pipeline-review-h2-2016
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Anemia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Anemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Have any query @ https://www.wiseguyreports.com/enquiry/643479-chemotherapy-induced-anemia-pipeline-review-h2-2016
Table of Content
Chemotherapy Induced Anemia Overview 8
Therapeutics Development 9
Pipeline Products for Chemotherapy Induced Anemia - Overview 9
Chemotherapy Induced Anemia - Therapeutics under Development by Companies 10
Chemotherapy Induced Anemia - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Chemotherapy Induced Anemia - Products under Development by Companies 15
Chemotherapy Induced Anemia - Companies Involved in Therapeutics Development 16
3SBio Inc. 16
BIOCAD 17
Chong Kun Dang Pharmaceutical Corp. 18
Dr. Reddy's Laboratories Limited 19
Galenica Ltd. 20
Panacea Biotec Limited 21
Pfizer Inc. 22
PharmaEssentia Corporation 23
PhytoHealth Corporation 24
Pieris Pharmaceuticals Inc 25
Sandoz International GmbH 26
SBI Pharmaceuticals Co., Ltd. 27
Therapure Biopharma Inc. 28
Tolero Pharmaceuticals, Inc. 29
Chemotherapy Induced Anemia - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Combination Products 31
Assessment by Target 32
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
(aminolevulinic acid hydrochloride + sodium ferrous citrate) - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
darbepoetin alfa - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
darbepoetin alfa - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
darbepoetin alfa - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
darbepoetin alfa - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
darbepoetin alfa - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
epoetin alfa - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
epoetin zeta - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
ferric carboxymaltose - Drug Profile 52
Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=643479
Continued…
Contact Info:
Name: NORAH TRENT
Email: Send Email
Organization: WiseGuy Research Consultant Pvt Ltd
Address: WISE GUY RESEARCH CONSULTANTS PVT LTD Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar Pune - 411028 Maharashtra, India Ph: +91 841 198 5042 info@wiseguyreports.com
Phone: +1-646-845-9349 (US) +44 208 133 9349 (UK)
Release ID: 138787